What BPC-157 Oral actually is

BPC-157 was originally identified in human gastric juice; oral administration delivers it directly to the GI mucosa. Sikiric and colleagues have published extensive animal data showing oral and injected BPC-157 are both biologically active, with oral form showing particular activity at GI sites.¹

At Luxbae we prescribe oral BPC-157 for patients with GI-specific goals — NSAID-induced gastropathy, post-antibiotic gut recovery, mild IBD adjunct support, or patients who prefer to avoid injections. The systemic effects of oral BPC-157 are less robust than injection.

At Luxbae, BPC-157 Oral is prescribed and supervised by Dr. Ernst von Schwarz, MD, PhD after a complimentary medical consultation.

Mechanism — Direct GI mucosal contact

Oral form delivers BPC-157 to gastric and intestinal mucosa, supporting the body-protection compound’s native environment.¹

What the research shows

Gastric mucosal protection. Documented activity against gastric ulcer models, NSAID injury.²

Intestinal barrier. Tight-junction integrity in animal models of leaky gut.

IBD adjunct. Animal data in colitis models; clinical use as adjunct.³

Side effects: Generally well-tolerated. Mild transient nausea, occasional loose stools in early dosing.

FDA note: Not FDA-approved. Compounded protocol under medical supervision.

BPC-157 Oral FAQ

Oral vs injection?
Oral is GI-targeted; injection is systemic. Goal drives choice.

Cycle length?
4–8 weeks typically; longer in chronic GI conditions.

References

1. Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2010;16(10):1224-1234.
2. Sikiric P, Petek M, Rucman R, et al. A new gastric juice peptide, BPC: characterization and effects. J Physiol Paris. 1993;87(5):313-327.
3. Klicek R, Sever M, Radic B, et al. BPC 157 in colitis and gut barrier. Inflammopharmacology. 2010.